Literature DB >> 21661203

[Neuropsychiatric side effects of antituberculosis agents].

L Fekih1, L Boussoffara, S Fenniche, H Abdelghaffar, M Lamine Megdiche.   

Abstract

UNLABELLED: Accurency of neurological or psychiatric complications secondary to the administration of antituberculosis may be at the origin of diagnosis and therapeutic problems. This work aims at studying the frequency of these manifestations, their clinical presentations and their therapeutic approach. PATIENTS AND METHODS: This retrospective study was carried on from January 1990 to June 2008 at Ibn Nafis Pulmonary Department of Abderrahmen Mami Hospital in Ariana. It dealt with 18 in-patients with a neurologic or a psychiatric complication due to antituberculous drugs. Peripheral neuropathy was noted in 6 patients (33%). One of them had a history of chronic alcoolism, another one had a history of diabetes mellitus and 2 other patients were more than 72 years old. We had definitively stopped isoniazide in 2 cases and decreased the dosage in 4 other patients. However, all patients received B6 vitamin. Convulsions occured in 2 women without any history of epileptic status. Anticonvulsivant treatment was prescribed and isoniazid definitively stopped. Hallucinosis was noted in 4 patients, with one having a history of chronic alcoolism. Isoniazide was stopped in all cases. Agressivity, insomnia and memory problems were noted in 6 patients. Isoniazid was interrupted in only one woman who had history of depression. In 5 other patients, anxiolytics were prescribed. Isoniazide was incrimined in all cases and evolution was favorable for the 18 patients. A close monitoring of patients on antituberculous treatment is required to detect the onset of any neuropsychiatric complications incriminating usually isoniazid. Definitive interruption or decrease of the dose of isoniazid depending of the acetylation test were necessary.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21661203

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  1 in total

1.  Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.

Authors:  Mariam El Hamdouni; Samir Ahid; Jamal Eddine Bourkadi; Jouda Benamor; Mohammed Hassar; Yahia Cherrah
Journal:  Infection       Date:  2019-06-04       Impact factor: 7.455

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.